☰

Jennifer N. Uram, Ph.D. - Publications

Affiliations: 
2009 Johns Hopkins University, Baltimore, MD 
Area:
Immunology, Oncology
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Le DT, Crocenzi TS, Uram JN, Lutz ER, Laheru D, Sugar EA, Vonderheide RH, Fisher GA, Ko AH, Murphy AL, McDougall K, Ferber S, Brockstedt DG, Jaffee EM. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal of Clinical Oncology. 34: TPS486-TPS486. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps486  0.687
2016 Le DT, Uram JN, Wang H, Kemberling H, Eyring A, Bartlett B, Goldberg RM, Crocenzi TS, Fisher GA, Lee JJ, Greten TF, Laheru D, Azad NS, Donehower RC, Luber B, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Journal of Clinical Oncology. 34: 195-195. DOI: 10.1200/Jco.2016.34.4_Suppl.195  0.482
2016 Diaz LA, Uram JN, Wang H, Bartlett B, Kemberling H, Eyring A, Azad NS, Dauses T, Laheru D, Lee JJ, Crocenzi TS, Goldberg RM, Fisher GA, Greten TF, Meyer CF, et al. Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. Journal of Clinical Oncology. 34: 3003-3003. DOI: 10.1200/Jco.2016.34.15_Suppl.3003  0.461
2016 Le DT, Uram JN, Wang H, Bartlett B, Kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology. 34: 103-103. DOI: 10.1200/Jco.2016.34.15_Suppl.103  0.483
2015 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine. 372: 2509-20. PMID 26028255 DOI: 10.1200/Jco.2015.33.18_Suppl.Lba100  0.378
2015 Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1325-33. PMID 25584002 DOI: 10.1200/Jco.2014.57.4244  0.695
2015 De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International Journal of Cancer. 136: 127-37. PMID 24832153 DOI: 10.1002/Ijc.28973  0.617
2015 Wang JS, Gootjes EC, Uram JN, Zahurak M, El-Khoueiry AB, Verheul HMW, Ahuja N, Azad NS. A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps797  0.436
2014 Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunology Research. 2: 949-61. PMID 25116755 DOI: 10.1158/2326-6066.Cir-14-0058  0.672
2014 Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Annals of Surgical Oncology. 21: 3931-7. PMID 24943235 DOI: 10.1245/S10434-014-3844-X  0.654
2014 Le DT, Laheru DA, Purtell K, Uram JN, Wang H, Lawrence S, Foreman E, David JJ, Parkinson R, Savage DT, Donehower RC, Rasheed Z, Zheng L, Azad NS, Cosgrove D, et al. A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 32: 4135-4135. DOI: 10.1200/Jco.2014.32.3_Suppl.213  0.419
2014 Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Journal of Clinical Oncology. 32: 177-177. DOI: 10.1200/Jco.2014.32.3_Suppl.177  0.623
2014 Patel RK, Ko AH, Onners B, Uram JN, Parkinson R, Sugar E, Lutz E, Zheng L, Laheru DA, Jaffee EM, Le DT. A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 32: TPS4160-TPS4160. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps4160  0.724
2014 Le DT, Azad NS, Laheru D, Browner IS, Wang H, Uram JN, Kemberling H, Zheng L, Iannone R, Friedman E, Meister A, Donehower RC, De Jesus-Acosta A, Diaz LA. Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. Journal of Clinical Oncology. 32: TPS3128-TPS3128. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3128  0.471
2013 Schueneman AJ, Sugar EA, Uram J, Bigelow E, Herman JM, Edil BH, Jaffee EM, Zheng L, Laheru DA. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Annals of Surgical Oncology. 20: S725-30. PMID 24046118 DOI: 10.1245/S10434-013-3262-5  0.641
2013 Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 382-9. PMID 23924790 DOI: 10.1097/Cji.0B013E31829Fb7A2  0.693
2013 Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Murphy A, Skoble J, Lemmens E, et al. Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 31: 4040-4040. DOI: 10.1200/Jco.2013.31.15_Suppl.4040  0.616
2013 Ng J, Uram J, Onners B, Biedrzycki B, Sugar E, Solt S, Armstrong T, Le D, Zheng L, Schroeder J, Jaffee E, Laheru D. Abstract B27: IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B27  0.679
2012 Le DT, Lutz E, Huang L, Onners B, Uram J, Solt S, Sugar E, Zheng L, Jaffee EM, Laheru D. Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 211. PMID 27983204 DOI: 10.1200/Jco.2012.30.4_Suppl.211  0.657
2012 Schueneman A, Sugar E, Uram J, Bigelow E, Herman JM, Edil BH, Jaffee EM, Zheng L, Laheru D. Association of low total lymphocyte count with overall and disease-free survival in patients with resected pancreatic adenocarcinoma receiving the GM-CSF secreting pancreatic tumor vaccine in combination with adjuvant chemoradiation. Journal of Clinical Oncology. 30: e14585-e14585. DOI: 10.1200/Jco.2012.30.15_Suppl.E14585  0.671
2011 Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. Journal of Immunology (Baltimore, Md. : 1950). 186: 3847-57. PMID 21346233 DOI: 10.4049/Jimmunol.1000361  0.656
Show low-probability matches.